ChromaDex posts Q4 net income of $0.1M; FY2023 revenue up 16% to $83.6M

Niagen Bioscience, Inc.

Q4 net sales $21.2M (+1% YoY); Tru Niagen sales $17.6M (+9% YoY).
Q4 gross margin 61.0% (up 380 bps); net income $0.1M vs loss of $1.4M prior year.
Full-year net loss improved $11.6M to $4.9M; positive Adjusted EBITDA of $1.9M.
Cash $27.3M, no debt; positive operating cash flow for fourth consecutive quarter.
Exceeded FY2023 outlook for gross margin and G&A; expects accelerated growth in 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Niagen Bioscience, Inc. reported Fourth Quarter 2023 results: revenue $21.2 million, net income net income of $0.1 million, EPS $0.00 earnings per share.

Period: Fourth Quarter 2023
Revenue: $21.2 million
Net income: net income of $0.1 million
EPS: $0.00 earnings per share
Result: reported results

Exact text from the filing

Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Niagen Bioscience, Inc. reported Fiscal Year 2023 results: revenue $83.6 million, net income net loss of only $4.9 million, EPS $0.07 loss per share.

Period: Fiscal Year 2023
Revenue: $83.6 million
Net income: net loss of only $4.9 million
EPS: $0.07 loss per share
Result: reported results

Exact text from the filing

Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and positive operating cash flows.

View on SEC.gov

Browse all earnings releases →

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-009383

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.